Nektar Therapeutics (NKTR) EBIT (2010 - 2026)

Nektar Therapeutics' EBIT history runs 17 years deep, the most recent figure standing at -$39.1 million for Q1 2026.

• On a quarterly basis, EBIT rose 12.31% year-over-year to -$39.1 million in Q1 2026; TTM through Mar 2026 was -$134.6 million, a 17.77% decrease from a year earlier, with the FY2025 full-year figure at -$140.1 million, down 33.18% from the prior year.
• EBIT retreated to -$39.1 million in Q1 2026 per NKTR's latest filing, from -$27.7 million in the prior quarter.
• Across five years, EBIT topped out at $14.3 million in Q4 2024 and bottomed at -$152.8 million in Q2 2022.
• The 5-year median for EBIT is -$44.5 million (2025), against an average of -$54.4 million.
• Across the five-year window, EBIT soared 142.82% in 2024 and slumped 292.81% in 2025, its largest moves.
• Year by year, EBIT stood at -$52.5 million in 2022, then jumped by 36.13% to -$33.5 million in 2023, then surged by 142.82% to $14.3 million in 2024, then slumped by 292.81% to -$27.7 million in 2025, then slumped by 41.17% to -$39.1 million in 2026.
• Per Business Quant, the three latest NKTR EBIT figures stand at -$39.1 million (Q1 2026), -$27.7 million (Q4 2025), and -$31.7 million (Q3 2025).